Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2011

2011

  • 2011 - 11 - 14

    Menarini Group Succeeds in Bid for Invida Group

    Singapore & Florence, Italy – November 15, 2011 – Singapore, Australia, China, Hong Kong, India, Indonesia, Malaysia, New Zealand, South Korea, Taiwan, Thailand, The Philippines, and Vietnam — these are the nations into which the Florence-based Italian multinational Menarini Group (Menarini) shall now be expanding following its acquisition of Invida Group Private Limited of Singapore (Invida).
  • 2011 - 11 - 13

    Invida Announces Acquisition of Dermatology and Primary Care Product Portfolios in India

    Singapore – November 14, 2011 – Invida Holdings Private Limited, the leading specialty biopharmaceutical company focused on the commercialization of healthcare brands throughout Asia-Pacific, announced the acquisition of a brand portfolio from India-based Shalaks Pharmaceuticals Pvt Ltd (Shalaks). No financial terms of the acquisition were disclosed. Upon acquisition of the product portfolio from Shalaks, Invida will market the products under the Invida brand.
  • 2011 - 05 - 23

    Singapore-based Invida Announces Expansion of Dermatology Portfolio Ahead of World Congress of Dermatology 2011

    Singapore - May 23, 2011: Invida Group Private Limited today announced plans to expand its dermatology portfolio to meet the needs of the rapidly expanding skin health sector in the region. Asia represents almost 25 percent of the world's dermatology market and is growing at a double-digit pace. Asia has high unmet needs in many areas of skin health, including dermatology, and many best in class medicines used in other parts of the world are not available in the region. Invida aims to change that by bringing important new treatments to the Asia-Pacific region to improve outcomes for patients in the areas of wound care, skin repair and dermatology.
  • 2011 - 04 - 10

    Invida to Present at the BioCentury Future Leaders in the Biotech Industry Conference

    Singapore – April 11, 2011 – Invida Group Pte Ltd, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia-Pacific, today announced that the company has been selected to present at the 2011 BioCentury Future Leaders in the Biotech Industry Conference held in New York on April 15, 2011. CEO John A. Graham will provide an updated overview of the Company, its strategy for 2011 and key partnering opportunities for growth in Asia-Pacific.
  • 2011 - 03 - 20

    Sinclair Pharma and Invida Group agree partnership deal for the commercialisation of Sinclair's leading brands in India

    London, UK, and Singapore - March 21, 2011 - Sinclair Pharma Plc ("Sinclair" or "the Company": SPH:L), the international specialty pharmaceutical company and Invida Holdings Private Limited ("Invida") are pleased to announce the inclusion of India into their long-term partnership for the commercialisation of Sinclair's market leading dermatology brands in the Asia-Pacific region. Invida is the region's leading specialty biopharmaceutical company with 4,000 employees and a presence in all major markets, including India.
  • 2011 - 02 - 15

    Invida Forms Unique Partnership With Roche In Korea

    Seoul, KOREA – February 15, 2011 – Invida Group Pte Ltd, the leading specialty pharmaceutical company focused on the commercialization of healthcare products throughout Asia-Pacific, today announced that it has entered into a partnership agreement with Roche for the commercialization and marketing of that company's primary care portfolio throughout Korea.
  • 2011 - 01 - 14

    Orexo and Invida Jointly Announce Agreement for Abstral in Asia-Pacific

    Uppsala, Sweden and Singapore – January 14, 2010 – Orexo AB (STO: ORX) and Invida Group Private Limited today announced the signing of an exclusive licensing and distribution agreement, covering the Asia-Pacific region for Abstral™, Orexo's product for the treatment of breakthrough cancer pain.